

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Examiner : Tamthom N. Truong
Group : 1624
Applicants : Jeffrey Saunders et al.
Serial No. : 10/750,326
Confirmation No. : 4684
Filed : December 31, 2003
For : INHIBITORS OF PHOSPHATASES

Cambridge, Massachusetts
April 2, 2008

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

STATEMENT OF SUBSTANCE OF INTERVIEW

Sir:

This is in response to an April 1, 2008 telephonic interview between Examiner Troung and applicant's representative, Michael C. Badia. A Statement of Substance of Interview (hereinafter "Statement") would likely be due May 1, 2008. Thus, this Statement is timely filed.

Remarks begin at page 2 of this Statement.

REMARKS

Applicants thank Examiner Tamthom Troung (hereinafter "Examiner Troung") for the courtesy of the telephonic interview that took place on April 1, 2008 with applicant's representative, Michael C. Badia (hereinafter "Mr. Badia").

Examiner Troung and Mr. Badia discussed the differences between each of the compound tables in the three prior art references of Fujimori et al. (e.g., EP 0456835 A1, EP 0456835 B1 and U.S. Patent No. 5,234,928). Examiner Troung clarified that the species within the compound tables in EP 0456835 A1 and in U.S. Patent No. 5,234,928 were relevant for the maintained rejections. Mr. Badia agreed to timely file an RCE and an appropriate response.

Conclusion

Should the Examiner decide that a further telephone discussion would be useful in the prosecution of the above application, applicants request that the Examiner contact the undersigned at her convenience.

Respectfully submitted,

/Michael C. Badia/
Michael C. Badia (Reg. No. 51,424)
Attorney for Applicants
c/o Vertex Pharmaceuticals Incorporated
130 Waverly Street
Cambridge, MA 02139-4242
Tel.: (617)444-6467
Fax.: (617)444-6483